Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 May 15:9:54.
doi: 10.1186/s13148-017-0353-3. eCollection 2017.

Epigenome-wide association of myocardial infarction with DNA methylation sites at loci related to cardiovascular disease

Masahiro Nakatochi #  1 , Sahoko Ichihara #  2 , Ken Yamamoto  3 , Keiko Naruse  4 , Shigeki Yokota  5 , Hiroyuki Asano  5 , Tatsuaki Matsubara  4 , Mitsuhiro Yokota  6
Affiliations
Clinical Trial

Epigenome-wide association of myocardial infarction with DNA methylation sites at loci related to cardiovascular disease

Masahiro Nakatochi et al. Clin Epigenetics. .

Abstract

Background: Development of cardiovascular disease (CVD), including coronary artery disease, arrhythmia, and ischemic stroke, depends on environmental and genetic factors. To investigate the epigenetic basis of myocardial infarction (MI), we performed an epigenome-wide association study for this condition in elderly Japanese subjects. A total of 192 case subjects with MI and 192 control subjects were recruited from hospital attendees and the general population, respectively. Genome-wide DNA methylation (DNAm) profiles for DNA isolated from whole blood were obtained by analysis with an Infinium HumanMethylation450 BeadChip. The relation of DNAm sites found to be significantly associated with MI to nearby single nucleotide polymorphisms (SNPs) previously shown to be associated with CVD was assessed in the control group.

Findings: Three DNAm sites (cg06642177, cg07786668, cg17218495) showed genome-wide significant associations with MI (p = 4.33 × 10-8, 3.96 × 10-10, and 3.77 × 10-8, respectively). Two of these sites (cg07786668, cg17218495) still showed such associations after adjustment for classical risk factors of MI (p = 1.04 × 10-7 and 6.60 × 10-8, respectively). The DNAm sites cg07786668 and cg17218495 are located in ZFHX3 (zinc finger homeobox 3) and SMARCA4 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4) genes, respectively. SNPs in ZFHX3 or SMARCA4 that were previously found to be associated with CVD were not significantly associated with these DNAm sites in our control subjects.

Conclusions: We identified two DNAm sites-cg07786668 in ZFHX3 and cg17218495 in SMARCA4- that are independently and significantly associated with MI. Our results suggest that the development of MI might be influenced by changes in DNAm at these sites via a pathway that differs from that affected by CVD-associated SNPs in these genes. The Kita-Nagoya Genomic Epidemiology (KING) study, which was the source of control samples in the present study, was registered in ClinicalTrials.gov (NCT00262691) on 6 December 2005.

Keywords: Cardiovascular disease; DNA methylation; Epigenome-wide association study; Myocardial infarction; Single nucleotide polymorphism.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Manhattan plot for EWAS analysis of DNAm and MI. The horizontal line represents the genome-wide significance level (α = 1.43 × 10−7). The p values were corrected for genomic control
Fig. 2
Fig. 2
Quantile-quantile (Q-Q) plot of observed versus expected –log10(p value) for tests of association between DNAm sites and MI. The p values were corrected for genomic control
Fig. 3
Fig. 3
Regional plots for the three DNAm sites that showed a genome-wide significant association with MI. The vertical axis represents –log10(p value) for assessment of the association of cg07786668 (a), cg17218495 (b), or cg06642177 (c) with MI. The DNAm sites that achieved a genome-wide significance level (α = 1.43 × 10−7) are shown as black triangles, those that achieved a nominal significance level (α = 0.05) are shown as gray squares, and other DNAm sites are shown as open circles
See this image and copyright information in PMC

References

    1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498–1504. doi: 10.1016/S0140-6736(96)07492-2. - DOI - PubMed
    1. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, et al. ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;2010(122):e584–636. - PubMed
    1. Kitakaze M. Trends in characteristics of CVD in Asia and Japan: the importance of epidemiological studies and beyond. J Am Coll Cardiol. 2015;66:196–198. doi: 10.1016/j.jacc.2015.05.035. - DOI - PubMed
    1. D'Agostino RB, Sr, Pencina MJ, Massaro JM, Coady S. Cardiovascular disease risk assessment: insights from Framingham. Glob Heart. 2013;8:11–23. doi: 10.1016/j.gheart.2013.01.001. - DOI - PMC - PubMed
    1. Consortium CAD, Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D, Erdmann J, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45:25–33. - PMC - PubMed

Publication types

Associated data